- Home
- CTRM vs CLSD Comparison
CTRM vs CLSD Comparison
Compare CTRM & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- CLSD
- Stock Information
- Founded
- CTRM 2016
- CLSD 2011
- Country
- CTRM Cyprus
- CLSD United States
- Employees
- CTRM N/A
- CLSD N/A
- Industry
- CTRM Marine Transportation
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- CLSD Health Care
- Exchange
- CTRM Nasdaq
- CLSD Nasdaq
- Market Cap
- CTRM 21.2M
- CLSD 21.5M
- IPO Year
- CTRM N/A
- CLSD 2016
- Fundamental
- Price
- CTRM $2.07
- CLSD $3.77
- Analyst Decision
- CTRM
- CLSD Hold
- Analyst Count
- CTRM 0
- CLSD 4
- Target Price
- CTRM N/A
- CLSD $65.00
- AVG Volume (30 Days)
- CTRM 36.9K
- CLSD 49.0K
- Earning Date
- CTRM 11-06-2025
- CLSD 11-11-2025
- Dividend Yield
- CTRM N/A
- CLSD N/A
- EPS Growth
- CTRM N/A
- CLSD N/A
- EPS
- CTRM N/A
- CLSD N/A
- Revenue
- CTRM $67,859,415.00
- CLSD $4,166,000.00
- Revenue This Year
- CTRM N/A
- CLSD $98.20
- Revenue Next Year
- CTRM N/A
- CLSD $213.77
- P/E Ratio
- CTRM N/A
- CLSD N/A
- Revenue Growth
- CTRM N/A
- CLSD N/A
- 52 Week Low
- CTRM $1.91
- CLSD $3.32
- 52 Week High
- CTRM $4.19
- CLSD $19.80
- Technical
- Relative Strength Index (RSI)
- CTRM 42.74
- CLSD 55.90
- Support Level
- CTRM $2.06
- CLSD $3.88
- Resistance Level
- CTRM $2.17
- CLSD $4.21
- Average True Range (ATR)
- CTRM 0.06
- CLSD 0.27
- MACD
- CTRM -0.00
- CLSD -0.18
- Stochastic Oscillator
- CTRM 6.25
- CLSD 13.10
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.